Lymph node ratio and breast cancer prognosis: A meta-analysis

Breast Cancer

Volumn 21, Issue 1, 2014, Pages 1-9

  Liu, Dechun ^a   Chen, Yanbin ^a   Deng, Miao ^a   Xie, Gangqiang ^a   Wang, Jianguang ^a   Zhang, Like ^a   Liu, Qipeng ^a   Yuan, Pengfei ^a   Feng, Xiaoshan ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Breast neoplasm; Lymph node ratio; Meta analysis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CAUSE SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; HUMAN; LYMPH NODE RATIO; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 84891524700     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-013-0497-8     Document Type: Review

References (32)

1. De Boer M, Van Dijck JAAM, Bult P, et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 2010;102:410-25.
2. Vinh-Hung V, Nguyen NP, Cserni G, et al. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol. 2009;5:1585-603.
3. Ahn SH, Kim HJ, Lee JW, et al. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Res Treat. 2011;130:507-15.
4. Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062-8.
5. Woodward WA, Vinh-Hung V, Ueno NT, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006;24:2910-6.
6. Ibrahim EM, Elkhodary TR, Zekri JM, et al. Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi Arabia. Asia Pac J Clin Oncol. 2010;6:130-7.
7. Dings PJM, Elferink MAG, Strobbe LJA, et al. The prognostic value of lymph node ratio in node-posjitive breast cancer: a dutch nationwide population-based study. Ann Surg Oncol 2013: 1-8.
8. Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be incorporated into staging for breast cancer. Ann Surg Oncol. 2011;18:S155.
9. Tendulkar RD, Rehman S, Shukla ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys. 2012;83:e577-81.
10. Saxena N, Hartman M, Yip CH, et al. Does the axillary lymph node ratio have any added prognostic value over pN Staging for south east Asian breast cancer patients? PLoS One. 2012;7(9):e45809.
11. Huang CJ, Hou MF, Chuang HY, et al. Comparison of clinical outcome of breast cancer patients with T1-2 tumor and one to three positive nodes with or without postmastectomy radiation therapy. Jpn J Clin Oncol. 2012;42:711-20.
12. Saxena N, Hartman M, Aziz R, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study. Eur J Cancer. 2011;47:1186-92.
13. Kim JY, Ryu MR, Choi BO, et al. The prognostic significance of the lymph node ratio in axillary lymph node positive breast cancer. J Breast Cancer. 2011;14:204-12.
14. Han TJ, Kang EY, Jeon W, et al. The prognostic value of the nodal ratio in N1 breast cancer. Radiat Oncol. 2011;6:131.
15. Karihtala P, Winqvist R, Bloigu R, et al. Long-term observational follow-up study of breast cancer diagnosed in women ≤ 40 years old. Breast. 2010;19:456-61.
16. Martinez-Ramos D, Escrig-Sos J, Alcalde-Sanchez M, et al. Disease-free survival and prognostic significance of metastatic lymph node ratio in T1-T2 N positive breast cancer patients. A population registry-based study in a European country. World J Surg. 2009;33:1659-64.
17. Keam B, Im SA, Kim HJ, et al. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2009;116:153-60.
18. Hatoum HA, Jamali FR, El-Saghir NS, et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol. 2009;16:3388-95.
19. Duraker N, Caynak ZC, Bati B. Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma? Ann Surg Oncol. 2008;15:430-7.
20. Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol. 2006;32:1082-8.
21. Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;103:2006-14.
22. Voordeckers M, Vinh-Hung V, Van de Steene J, et al. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004;70:225-30.
23. van der Wal BC, Butzelaar RM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol. 2002;28:481-9.
24. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20:707-18.
25. Schneeweiss A, Goerner R, Hensel MA, et al. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy. Biol Blood Marrow Transpl. 2001;7:332-42.
26. Nieto Y, Cagnoni PJ, Shpall EJ, et al. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res. 1999;5:3425-31.
27. Vinh-Hung V, Joseph SA, Coutty N, et al. Age and axillary lymph node ratio in postmenopausal women with T1-T2 node positive breast cancer. Oncologist. 2010;15:1050-62.
28. Lale Atahan I, Yildiz F, Ozyigit G, et al. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol. 2008;47:232-8.
29. Truong PT, Woodward WA, Thames HD, et al. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2007;68:59-65.
30. Ferrari A, Rovera F, Dionigi P, et al. Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer. Expert Rev Anticancer Ther. 2006;6:1503-15.
31. Baslaim MM, Al Malik OA, Al-Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg. 2002;184:299-301.
32. Schaapveld M, Otter R, de Vries EG, et al. Variability in axillary lymph node dissection for breast cancer. J Surg Oncol. 2004;87:4-12.